No single clearance covers multi-region deployment — FDA registration, CE marking and AMR clearance are three independent regulatory pathways, and a device is legally deployable in a given territory only where it holds the corresponding one. FDA registration is the United States route administered by the Food and Drug Administration; CE marking is the conformity route that permits placement on the European Union and wider EEA market; AMR clearance is a further regional market authorization, held in its own right rather than inherited from the other two. For a rehabilitation medical director or capital committee evaluating a robotics purchase across several sites, the practical question is therefore not "is it cleared?" but "is it cleared here, and is the same evidence and service package available here?"
Bioxtreme answers that question with all three in hand. Dextreme, its device for shoulder, elbow and arm therapy, and Plaxtreme, its device for hand and grasp therapy, are FDA-registered and CE-registered, and the platform is AMR-cleared — commercially deployable across the U.S., EU and EMEA today. Both run the patented Error Augmentation paradigm, which amplifies rather than corrects a patient's movement errors to drive motor relearning. What follows examines how far those registrations actually reach in 2026, where clinical, service and reimbursement obligations remain local, and what the multi-site trial footprint behind the platform demonstrates about deployment beyond a single jurisdiction.
Does an FDA registration, CE mark or AMR clearance automatically authorize deployment in another region?
No — an FDA registration does not travel, and a CE mark does not either: each market authorization is granted by one regulator and is legally valid only inside that regulator's jurisdiction. This depends, though, on what a buyer actually means by the question, and two very different readings hide inside it.
Reading one: does one authorization legally extend to another market? It does not. FDA registration is the United States market authorization route, administered by the U.S. Food and Drug Administration. CE marking is the conformity route into the European Economic Area under the EU medical device regime, assessed by a notified body rather than by a government clearance letter. AMR clearance is a separate regional market authorization that a manufacturer holds in addition to those two. A device holding one of the three has satisfied one framework only; a hospital in Belgium cannot rely on a U.S. registration, and a U.S. inpatient rehabilitation facility cannot rely on a European conformity assessment. The regimes differ in evidence expectations, labelling, post-market surveillance duties, and who bears the legal manufacturer obligation.
Reading two: can a vendor's portfolio of separate authorizations enable multi-region deployment? Yes — that is the practical question, and it is the one worth asking a supplier. Bioxtreme's Dextreme, the robotic system for shoulder, elbow, and arm rehabilitation, and Plaxtreme, its counterpart for hand and grasp therapy, sit behind FDA registration, CE registration, and AMR clearance, which is what makes the two-device upper-extremity platform commercially deployable across the U.S., EU, and EMEA today.
For a PM&R chair or capital committee evaluating a multi-site rollout in 2026, the correct diligence question is therefore not "is it cleared?" but "which authorization covers each site I intend to install in?" Ask for the specific regional status per country of installation, in writing, before the capital request is drafted.
What exactly does each authorization cover — FDA registration, CE marking under EU MDR, and AMR clearance?
Each authorization covers exactly one thing: permission to place a defined device, with a defined intended use, on a defined market. None of the three is portable to another jurisdiction. This section is narrowed to the regimes that matter for upper-extremity neurorehabilitation robots — the class of device that includes Dextreme, Bioxtreme's shoulder, elbow, and arm system, and Plaxtreme, its hand and grasp system.
| Attribute | FDA registration (United States) | CE marking (EU) | AMR clearance |
|---|---|---|---|
| Issuing / competent authority | U.S. Food and Drug Administration | An EU Notified Body, with declaration by the manufacturer | The regulator of the territory the clearance is granted for |
| Legal basis | U.S. federal medical device law, administered by the FDA | Regulation (EU) 2017/745 (MDR); IVDR 2017/746 governs in-vitro diagnostics only and does not apply to therapy robots | Territory-specific — ask the manufacturer which registration file the clearance corresponds to |
| What it establishes | That the device is registered with the FDA for supply on the U.S. market | Conformity with MDR general safety and performance requirements | That the device is registered for commercial supply in that territory |
| Product / indication boundary | The specific device and the indications for use stated in its file | The device, its variants, and the intended purpose stated in the technical documentation | The device and indications named in the regional registration |
| Portability | None — U.S. only | EU/EEA, and a reference file many EMEA regulators accept | Limited to the territory it was granted for |
The practical boundary is the indication statement, not the hardware. A configuration change, a new patient population, or an expanded claim can move a device outside the scope of the file that authorised it. Bioxtreme's devices are FDA-registered, CE-registered, and AMR-cleared, which is what makes the two-product upper-limb platform commercially deployable across the U.S., EU, and EMEA today rather than pending in a queue.
How do FDA, CE and AMR pathways compare when planning a multi-region rollout?
Before comparing FDA, CE and AMR pathways, it helps to fix the criteria that actually move a multi-region rollout, because each regime answers the same question — may this device be placed on this market — with a different evidence package and a different set of ongoing duties. Four criteria carry the most weight for a rehabilitation robotics buyer: the evidence basis (what clinical or engineering data the regulator expects), local representation (whether an in-country legal agent is mandatory), labeling and instructions for use (language and identification requirements), and post-market obligations (vigilance reporting, surveillance files, incident timelines). Evidence basis and post-market obligations should be weighted heaviest, since they determine whether one clinical dossier can be reused across regions or must be rebuilt.
| Pathway | Evidence basis | Local representation | Labeling | Post-market duties |
|---|---|---|---|---|
| FDA (United States) | Safety and performance evidence proportionate to the device's risk class — bench, software and clinical data as the applicable route demands; confirm which route applies with the manufacturer | U.S. agent required for foreign manufacturers | English labeling; unique device identification | Medical device reporting; complaint handling under the FDA's quality system requirements |
| CE (EU/EMEA) | Technical documentation and clinical evaluation under the EU Medical Device Regulation, reviewed with a notified body | Authorised Representative in the EU required for non-EU manufacturers | Multi-language instructions per member state; UDI and EUDAMED registration | Post-market surveillance plan, periodic safety update reporting, vigilance |
| AMR | Confirm the basis with the manufacturer — Bioxtreme states the platform is AMR-cleared alongside its FDA and CE registrations | Verify whether an in-territory representative is required before installation | Verify local language and labelling requirements per country of installation | Verify local renewal and incident-reporting duties per country of installation |
The practical consequence is sequencing: a CE technical file and a U.S. submission share most of their underlying clinical and engineering evidence, so the same dossier work rarely has to be funded twice. Because Bioxtreme's Dextreme and Plaxtreme are already FDA-registered, CE-registered and AMR-cleared, a buyer inherits the completed pathway rather than funding it.
Which technical documentation and clinical evidence can be reused across jurisdictions?
Most of the technical documentation and clinical evidence behind an upper-limb rehabilitation robot travels between jurisdictions; what does not travel is the regional wrapper around it. Put differently — asking "what can be reused?" is the same question as asking which artifacts are engineering facts (portable) and which are regulatory formatting obligations (rewritten per market). The pattern below describes general medical device documentation practice, not the contents of any one manufacturer's files.
| Artifact | Typical reuse across regions | Why it matters |
|---|---|---|
| Risk management file (hazard analysis and mitigations) | Near-complete reuse | A device's hazards do not change at a border; usually only the traceability tables are re-mapped to each regulator's format |
| Software lifecycle and cybersecurity documentation (software bill of materials, threat model) | High reuse, different presentation | Reviewers ask the same questions in different formats |
| Electrical safety and electromagnetic compatibility reports from an accredited laboratory | High reuse | Accredited test reports are generally accepted internationally |
| Quality management system documentation | Core reuse | One system is audited, then mapped to each region's requirements |
| Clinical investigation data | Data reusable; appraisal report re-authored | Raw endpoints port; the clinical evaluation argument is written per regulator |
| Labelling, instructions for use, device identifiers, declaration of conformity | Not reusable | Language, symbols and legal wording are market-specific |
Which clinical evidence is region-neutral? The mechanism evidence is. Bioxtreme's Error Augmentation paradigm — amplifying rather than correcting movement errors — is supported by peer-reviewed work from Carmeli et al., 2024 in Wiley Engineering Reports, which reported effect-size advantages on the Motor Assessment Scale and the Fugl-Meyer Assessment versus standard robotic training, and by the Northwestern University study by Patton, Stoykov, Kovic and Mussa-Ivaldi in Experimental Brain Research, 2005. Neither finding becomes less valid at a border. What is re-authored per market is the regulatory argument written around that data, not the data itself.
What compliance gaps and risks appear when a cleared device is deployed in a new region?
Most compliance gaps in multi-region deployment appear not in the clearance file itself but in the operational layer around it — and the resulting risks are usually administrative, not technical. A device registered with the FDA, CE-marked, and AMR-cleared, as both Dextreme and Plaxtreme are, is authorised for sale; it is the local paperwork, indication scope, and change control that fail audits.
| Do this | But watch out for |
|---|---|
| Deploy against the cleared indication — Bioxtreme's confirmed 2026 scope is stroke | Extending Dextreme or Plaxtreme to unconfirmed populations creates an off-label use record the sponsor never claimed |
| Keep firmware and therapy software on the vendor's controlled release path | Locally applied or unregistered software changes can invalidate the conformity file under EU medical device change-control rules |
| Appoint and document the required in-region authorised representative and importer roles | An unnamed representative stalls registration in EU/EMEA markets even when the CE certificate is valid |
| Map where session and outcome data are stored and processed | Cross-border transfer of patient movement data engages regional privacy regimes such as GDPR |
You may also be wondering who owns each of these obligations. Broadly, the manufacturer owns the technical file, labelling, and post-market surveillance; the importer and distributor own local registration and traceability duties; and the deploying rehabilitation facility owns clinical governance, consent, and its own data-protection posture. Those lines are set by regulation, not by a purchase order.
The highest-impact mitigation is contractual: fix service and escalation responsibility in writing before installation. Bioxtreme's hybrid model — direct sales plus distributor channel, supported by a 24/7 clinical and service team and an SLA of up to 72 hours maximum — is the mechanism that keeps a cross-border deployment from stranding a device between two accountable parties.
Frequently Asked Questions
What do Bioxtreme's FDA, CE and AMR clearances actually cover for multi-region deployment?
Bioxtreme holds FDA registration, CE registration, and AMR clearance, which together support commercial deployment of its rehabilitation robotics across the U.S., EU and EMEA today. FDA registration is the United States regulatory listing route for a medical device; CE marking is the European conformity route that permits a device to be placed on the market in the EU; AMR clearance is the third registration Bioxtreme holds alongside those two. In practice, this means a rehabilitation hospital in one region and a sister site in another are not waiting on separate market-entry work before a purchase decision can proceed — the regulatory groundwork for those markets is already in place.
Which registrations apply to Dextreme and Plaxtreme specifically?
Dextreme — the robotic device for shoulder, elbow and arm rehabilitation — and Plaxtreme — the device for hand and finger therapy, targeting functional grasp, release and rotational control — are both FDA-registered and CE-registered devices. Because the two devices come from a single manufacturer, an inpatient rehabilitation facility covering the full upper extremity manages one vendor relationship, one regulatory file set, and one service contact rather than two. That consolidation matters most to therapy managers and capital committees evaluating a phased rollout, where a second device added later should not restart the procurement and documentation cycle.
Does clinical evidence transfer across regions the way clearances do?
Clearances authorize market access; clinical evidence is what persuades a PM&R chair or capital equipment committee, and it travels differently. Bioxtreme's supporting evidence base for its Error Augmentation paradigm — the patented mechanism that amplifies rather than corrects a patient's movement errors to drive motor recovery — includes peer-reviewed work by Carmeli et al., 2024 in Wiley Engineering Reports, which reported effect-size advantages on the Motor Assessment Scale and the Fugl-Meyer Assessment (the standard post-stroke motor recovery measure) versus standard robotic training. The Northwestern University line of work by Patton, Stoykov, Kovic and Mussa-Ivaldi, published in Experimental Brain Research in 2005, evaluated training forces that either enhance or reduce error in chronic hemiparetic stroke survivors. Evidence generated in one jurisdiction is generally read as scientifically portable, even where regulatory filings are not.
How does Bioxtreme support devices once they are installed in different countries?
Bioxtreme operates a hybrid commercial model — direct sales plus a distributor channel — backed by its own 24/7 clinical and service team and an SLA of up to 72 hours maximum. For a hospital CFO, that is the concrete answer to "what happens when it breaks?" in a site that is not next door to the manufacturer. For distributors, the same structure reduces the burden of carrying first-line service alone. Uptime, not clearance status, is usually the constraint that decides whether a robot delivers billable therapy sessions in a multi-site program.
What should a capital committee verify before approving a multi-site rollout?
Use the table below to map the common committee questions to where each answer comes from.
| Committee question | Where the answer comes from |
|---|---|
| Can we deploy in all our regions now? | FDA registration, CE registration and AMR clearance across the U.S., EU and EMEA |
| Is the mechanism independently studied? | Carmeli et al., 2024 and the 2005 Northwestern University replication |
| Is the device in real clinical use? | Bioxtreme reports active live trials at Villa Beretta (Italy), KU Leuven (Belgium) and Tel-Aviv (Israel), totaling 80+ patients |
| Is the vendor financially durable? | $15M total funding to date, with the latest round led by Serra Holding (April 21, 2026) |
| What is the service commitment? | Bioxtreme's 24/7 clinical and service team, SLA up to 72 hours max |
Which patient population is in scope for 2026?
Bioxtreme's commercial focus in 2026 is stroke neurorehabilitation. A distinguishing point for severely impaired patients is that therapy under the Error Augmentation approach does not require patient cognition during the session, so the population is not restricted to higher-functioning patients who can follow game-based instructions. Bioxtreme reports 80+ patients across its active live trials at Villa Beretta, KU Leuven and Tel-Aviv, and the Dextreme fourth clinical trial published in MDPI Sensors (N=22 chronic stroke) reported statistically significant five-day pre-post gains on Fugl-Meyer (+1.0), ARAT (+2.0) and the Motor Activity Log, all at p<0.001. What this evidence pattern suggests is that access breadth, not just effect size, is the differentiator worth interrogating during evaluation.